1360464-27-2

Upstream product

• 4746-97-8 cyclohexanedione monoethylene ketal 
• 813445-18-0 ethyl (R)-8-((1-phenylethyl)amino)-1,4-dioxaspiro[4.5]dec-7-ene-7-carboxylate 
• 813445-19-1 ethyl (8R,9S)-8-[[(1R)-1-phenylethyl]amino]-1,4-dioxaspiro[4.5]decane-9-carboxylate 
• 813445-20-4 (7R,8R)-8-((R)-1-phenyl-ethylamino)-1,4-dioxa-spiro[4.5]decane-7-carboxylic acid ethyl ester 
• 813445-21-5 [(7R,8R)-8-((R)-1-phenyl-ethylamino)-1,4-dioxa-spiro[4.5]dec-7-yl]-methanol 
• 813445-22-6 ((7R,8R)-8-Amino-1,4-dioxa-spiro[4.5]dec-7-yl)-methanol 
• 813445-23-7 ((7R,8R)-7-Hydroxymethyl-1,4-dioxa-spiro[4.5]dec-8-yl)-carbamic acid benzyl ester 
• 1360464-23-8 C₂₃H₂₇NO₄S 
• 1360464-24-9 C₂₃H₂₇NO₆S 
• 1360464-28-3 C₂₁H₂₃NO₅S 
• 1360464-25-0 C₂₁H₂₆N₂O₄S 
• 14160-65-7 ethyl 8-oxo-1,4-dioxaspiro[4.5]decane-7-carboxylate 

Relevant academic research and scientific papers

Synthesis of 3-phenylsulfonylmethyl cyclohexylaminobenzamide-derived antagonists of CC chemokine receptor 2 (CCR2)

We report the synthesis of 3-phenylsulfonylmethyl cyclohexylaminobenzamides (4) as CCR2 inhibitors for the potential treatment of inflammatory diseases. Several of the compounds display nanomolar binding affinity for CCR2. The in vitro structure-activity